Fatty-acid-based antimiR-23b allows brain delivery and reverses DM1 CNS defects in DMSXL mice
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by the expansion of CTG repeats in the 3′ untranslated region of DMPK. Although skeletal muscle and cardiac manifestations are among the most recognized features of the disease, DM1 also affects the central nervous system (CNS) and impacts significantly patients’ quality of life, with manifestations ranging from cognitive and behavioral abnormalities to sleep disturbances and, in the congenital form of the disease (CDM), severe neurodevelopmental impairment.
Authors
- Beatriz Llamusí (ORCID: https://orcid.org/0000-0002-2694-1293)
- Geneviève Gourdon (ORCID: https://orcid.org/0000-0002-3319-1347)
- Estefanía Cerro-Herreros (ORCID: https://orcid.org/0000-0003-3247-5900)
- Ruben D. Artero (ORCID: https://orcid.org/0000-0003-1596-047X)
- Diego Piqueras‐Losilla (ORCID: https://orcid.org/0009-0003-2667-234X)
Institutions
- Inserm (FR)
- Universitat de València (ES)
- Instituto de Salud Carlos III (ES)
- Sorbonne Université (FR)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- INCLIVA Health Research Institute (ES)
- Centre de Recherche en Myologie (FR)
- Menéndez Pelayo International University (ES)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.omtn.2026.103166
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00